September 25, 2019 / 8:16 PM / a month ago

Enanta Pharma's liver disease drug meets mid-stage study goal

Sept 25 (Reuters) - Enanta Pharmaceuticals Inc said on Wednesday its drug to treat non-alcoholic steatohepatitis (NASH) met the main goal of reducing levels of elevated liver enzymes in a mid-stage study.

The company said its experimental drug significantly reduced the levels of alanine aminotransferase (ALT) versus a placebo. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below